2HJ Stock Overview Brighter AB (publ), a health-tech company, develops solutions for the treatment of chronic condition in Sweden and internationally. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Brighter AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Brighter Historical stock prices Current Share Price €0.0001 52 Week High €0.042 52 Week Low €0.0001 Beta 1.62 1 Month Change 0% 3 Month Change 0% 1 Year Change -99.76% 3 Year Change -99.99% 5 Year Change n/a Change since IPO -99.99%
Recent News & Updates
Nasdaq Stockholm AB Decides to Delist the Shares and Equity Rights of Brighter AB Nov 24
Nasdaq Stockholm imposes a fine on Brighter AB (publ) Nov 23
Brighter AB (Publ) Applies for Corporate Restructuring in Bid for Longer-Term Financing Nov 02
Brighter AB (publ) Announces Executive Changes Sep 07 Brighter AB (publ) to Report Fiscal Year 2022 Results on Apr 13, 2023
Second quarter 2022 earnings released: kr0.05 loss per share (vs kr0.21 loss in 2Q 2021) Aug 26 See more updates
Nasdaq Stockholm AB Decides to Delist the Shares and Equity Rights of Brighter AB Nov 24
Nasdaq Stockholm imposes a fine on Brighter AB (publ) Nov 23
Brighter AB (Publ) Applies for Corporate Restructuring in Bid for Longer-Term Financing Nov 02
Brighter AB (publ) Announces Executive Changes Sep 07 Brighter AB (publ) to Report Fiscal Year 2022 Results on Apr 13, 2023
Second quarter 2022 earnings released: kr0.05 loss per share (vs kr0.21 loss in 2Q 2021) Aug 26
Brighter AB (Publ.) Announces its Actiste® Receives Telecommunication Type Approval in the United Arab Emirates Aug 03
High number of new and inexperienced directors Aug 01
Brighter AB (publ) Receives Final Approvals for Pilot Research with Insulin-Treated Diabetes Patients in the UAE Jul 22
High number of new and inexperienced directors Jul 02
Brighter's Interim CEO Erik Lissner Takes Permanent Role as the Company CEO Jul 01
Brighter AB Announces Actiste®, for the First Time, Is Prescribed to A Patient Living with Diabetes in Qatar Jun 15
700Brighter AB Announces Actiste, for the First Time, Is Prescribed to A Patient Living with Diabetes in Qatar Jun 14
Brighter AB (Publ) Announces Appointment of Johnny Ludvigsson as Board Member Jun 09
Brighter AB (publ) Announces First Patient Recruited for the Actiste Study in the United Kingdom Jun 03
First quarter 2022 earnings released: kr0.07 loss per share (vs kr0.20 loss in 1Q 2021) May 05
High number of new and inexperienced directors Apr 27
Full year 2021 earnings released: kr0.60 loss per share (vs kr1.08 loss in FY 2020) Apr 16
Brighter AB (Publ) Announces Launch and Commercial Availability of its Actiste® Service, Aiming to Improve the Quality of Life for People Living with Diabetes in Qatar Mar 23
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 02
Brighter AB (publ) to Report Fiscal Year 2021 Results on Apr 13, 2022 Mar 01 Brighter AB (publ) to Report Q3, 2022 Results on Nov 09, 2022
Brighter AB (publ), Annual General Meeting, May 05, 2022 Feb 10 Brighter AB (publ) has completed a Composite Units Offering in the amount of SEK 117.093404 million. Jan 28
Brighter AB (publ) announces positive results for Actiste® Dec 22
A shareholder of Blodtrycksdoktorn AB entered into an agreement to acquire an unknown stake in Blodtrycksdoktorn AB from Brighter AB (publ) (OM:BRIG) for SEK 5 million. Dec 17
Beijing AddLife AB (publ) (OM:ALIF B) acquired Camanio AB from Brighter AB (publ) (OM:BRIG) for SEK 65 million. Dec 02
Third quarter 2021 earnings released: kr0.20 loss per share (vs kr0.18 loss in 3Q 2020) Nov 20
Brighter's Actiste Receives Final Outstanding Approval in Qatar Sep 21
Interim Chief Financial Officer Julie Silber has left the company Aug 18
Second quarter 2021 earnings released: kr0.20 loss per share (vs kr0.27 loss in 2Q 2020) Aug 13
Brighter's Actiste Receives Telecommunication Approval in Qatar Jul 02
Brighter's Actiste Mini Receives Telecommunication Approval in Qatar Jun 18
Compatibility with New Insulins Opens Up New Market Opportunities for Brighter's Actiste Jun 08
Brighter AB (Publ) Launches Innovative Pilot Project with Tomelilla Municipality Jun 05
Brighter AB (Publ) Provides Revenue Guidance for the Year 2021 May 22
Brighter AB (Publ) Makes Progress with the User Experience Test of the Diabetes Management Solution Actiste May 18
First quarter 2021 earnings released: kr0.20 loss per share (vs kr0.19 loss in 1Q 2020) May 13
Brighter AB (Publ) Announces the Patent to Safely Combine MDD and IVDD Functionality into One Unit May 05
Full year 2020 earnings released: kr1.04 loss per share (vs kr1.06 loss in FY 2019) Feb 28 Brighter AB (publ) to Report Q4, 2021 Results on Feb 20, 2022
Brighter Signs 5-Year Distribution Agreement for Actiste in Qatar Feb 19
Brighter AB (publ) Announces CEO Changes Feb 08
Brighter AB (publ) Announces Diabetes Management Devices Actiste and Actiste Mini Receives Market Approval in Thailand Jan 09
Brighter AB (publ) Announces Clarification of Information Regarding Agreements for Nigeria and Ghana Jan 06 Brighter AB (publ) Signs 5-Year Agreement with Wssonlines Nigeria Ltd and Receives Initial Order for Actiste® Worth Eur 2.3 Million in Nigeria
Brighter AB (publ)'s Actiste® Mini Receives Market Approval in the Kingdom of Saudi Arabia Dec 20 Brighter AB (Publ) Announces Nomination Committee for the AGM 2021
New 90-day high: €0.31 Nov 22
Brighter AB (publ) Announces Executive Changes Nov 21
Brighter's Pioneering Diabetes Management Solution Actiste® Receives Market Approval in the United Arab Emirates Nov 10
Third quarter 2020 earnings released: kr0.16 loss per share Nov 07 Brighter AB (Publ) Announces Actiste Device and Its Associated Digital Platform Received Market Approval from the Saudi Food and Drug Authority
Founder & Executive Director recently sold €143.8k worth of stock Sep 14
First half earnings released Sep 05
First half earnings released Sep 02 Brighter AB (publ) to Report Q4, 2020 Results on Feb 12, 2021
New 90-day low - €0.30 Aug 25
New 90-day low - €0.30 Jul 20 Shareholder Returns 2HJ DE Medical Equipment DE Market 7D 0% -3.3% -2.0% 1Y -99.8% -8.5% 6.9%
See full shareholder returns
Return vs Market: 2HJ underperformed the German Market which returned -16.6% over the past year.
Price Volatility Is 2HJ's price volatile compared to industry and market? 2HJ volatility 2HJ Average Weekly Movement 1,761.6% Medical Equipment Industry Average Movement 6.7% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2HJ's share price has been volatile over the past 3 months.
Volatility Over Time: 2HJ's weekly volatility has increased from 887% to 1762% over the past year.
About the Company Founded Employees CEO Website 2007 57 Erik Lissner brighter.se
Brighter AB (publ), a health-tech company, develops solutions for the treatment of chronic condition in Sweden and internationally. It is developing Actiste, a daily diabetes care of insulin-treated diabetes; Actiste Mini for the treatment of non-insulin-treated diabetes; and Nectarine Health, an AI-based monitoring solution. The company offers its products to patients and their relatives, healthcare providers, authorities and governments, insurance companies and employers, pharmaceutical industry, clinical research organizations, and academic organizations.
Show more Brighter AB (publ) Fundamentals Summary How do Brighter's earnings and revenue compare to its market cap? 2HJ fundamental statistics Market cap €14.76m Earnings (TTM ) -€16.94m Revenue (TTM ) €3.05m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2HJ income statement (TTM ) Revenue SEK 33.03m Cost of Revenue SEK 10.88m Gross Profit SEK 22.15m Other Expenses SEK 205.85m Earnings -SEK 183.70m
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 29, 2022
Earnings per share (EPS) -0.21 Gross Margin 67.05% Net Profit Margin -556.20% Debt/Equity Ratio 1.7%
How did 2HJ perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2022/11/27 23:54 End of Day Share Price 2022/11/25 00:00 Earnings 2022/06/30 Annual Earnings 2021/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Brighter AB (publ) is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Christopher Uhde ABG Sundal Collier Sponsored Mats Hyttinge Carlsquare AB Maxim Jacobs Edison Investment Research
Show 0 more analysts 
